ArticleJournal of hand surgery global online2025
Sustained Serotonergic Stimulation Platform for Peripheral Axonal Regeneration.
Article in Journal of hand surgery global online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Limitations remain in peripheral nerve injury treatments. Previous studies suggest that serotonergic signaling promotes nerve regeneration by facilitating reinnervation and modulating neuronal guidance. This study aimed to evaluate the potential of serotonergic peripheral neuroregeneration using Zolmitriptan, a serotonin receptor agonist. Methods: A total of 24 female Sprague-Dawley rats were divided into four nerve injury cohorts. Sciatic nerve transection and primary repair were performed in two groups, whereas a 1-cm nerve defect was created and repaired with the same nerve segment as an autograft in the other two groups. One primary repair group and one nerve graft group received 1 mL of Zolmitriptan directly to the nerve via sonicated silk protein gels. Control groups received gels without Zolmitriptan. At postoperative 8 weeks, the sciatic nerves were collected for histological analysis. Ex vivo diffusion tensor magnetic resonance imaging was also used to assess axonal regeneration. Results: The primary repair cohort treated with Zolmitriptan demonstrated robust regeneration, whereas the control cohort showed poorer regeneration. There was no statistical difference in regeneration between the treated and control autograft groups. When evaluating the regeneration rates of the primary repair groups, 80% of the axons successfully extended to the distal end in the Zolmitriptan group, compared with 57% in the control group. In the autograft groups, these rates were 65% for Zolmitriptan and 42% for the control. Electron microscopy supported the axonal counting results. Conclusions: This pilot study suggests that Zolmitriptan may enhance peripheral nerve regeneration following transection injuries, warranting further investigation for clinical translation. Clinical relevance: This study presents promising results regarding the potential of serotonin agonists to aid in peripheral nerve recovery. Additional investigation into these findings could inform new treatment strategies for peripheral nerve injuries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.